Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy for Sleep Disturbance in Advanced Cancer
NCT05474846Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melatonin, methylphenidate hydrochloride extended-release chewable tablet in sleep disorder, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2022; status: active, not recruiting.
02
Drugs
melatoninmethylphenidate hydrochloride extended-release chewable tablet
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NCT05474846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05474846.